
Enovis Corp (ENOV) Stock Forecast & Price Target
Enovis Corp (ENOV) Analyst Ratings
Bulls say
Enovis is supported by solid 3Q26 execution, with revenue of $558.7M, 4.6% organic growth, adjusted EBITDA of $104M, and non-GAAP EPS of $0.88 all beating consensus while margins expanded meaningfully. Its outlook is strengthened by a favorable product mix and share gains in higher-growth Reconstructive offerings such as Nebula, ARVIS, and shoulder and extremities, alongside steadier Prevention & Recovery cash flow from bracing, Recovery Sciences, and BoneStim. Free cash flow of $35M, leverage falling to 2.9x from 3.1x, a raised 2026 EBITDA and EPS outlook, and a new $200M buyback all signal improving financial quality and shareholder-friendly capital allocation.
Bears say
Enovis is facing a negative outlook because its growth profile remains too dependent on Prevention & Recovery, where low-single-digit growth is offset by softer Western European volumes, tariff pressure, Middle East conflict, and a roughly 180 bps revenue headwind from the Dr. Comfort divestiture. Management’s FY26 guidance only implies $2.32B-$2.35B of revenue and $428M-$438M of adjusted EBITDA, while the eCential Robotics acquisition is expected to dilute adjusted EBITDA margin by about 150 bps in 2027, underscoring integration and dilution risk. Competitive pressure in reconstructive surgery, slower-than-expected market share gains, and continued operating margin contraction could keep earnings below expectations and limit valuation support.
This aggregate rating is based on analysts' research of Enovis Corp and is not a guaranteed prediction by Public.com or investment advice.
Enovis Corp (ENOV) Analyst Forecast & Price Prediction
Start investing in Enovis Corp (ENOV)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Enovis Corp (ENOV) Forecast
Enovis Corp (ENOV) Analyst Forecast & Price Prediction
Start investing in Enovis Corp (ENOV)
Order type
Buy in
Order amount
Est. shares
0 shares